Using the diabetes drug Actos for one year or more increases the risk of being diagnosed with bladder cancer by 39% according reports reviewed by the FDA in 2011. Even though the diabetes drug Actos (generic name: pioglitazone) has been taken off the market by the drug regulators of Germany, France, and India because of safety concerns, The Food and Drug Administration (FDA), despite issuing several safety communications about the drug, still allows Actos to be marketed in the United States. The FDA continues to evaluate the data.… Read More